ArticleCureus2026
Unexpected Durable Treatment-Free Disease Control After Acalabrutinib Cessation: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We describe a man diagnosed with chronic lymphocytic leukaemia (CLL) at the age of 80 who achieved sustained disease control following discontinuation of acalabrutinib. Initially managed with a watch-and-wait approach, treatment was initiated after evidence of disease progression. Acalabrutinib was commenced but subsequently stopped due to significant adverse effects, including severe anaemia requiring transfusion support. Unexpectedly, serial blood monitoring after cessation demonstrated persistent stability of lymphocyte counts without further CLL-directed therapy. To our knowledge, this represents a rare example of durable treatment‑free disease control following acalabrutinib discontinuation, highlighting the need for further research into predictors of sustained remission after targeted therapy withdrawal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.